Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443391 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT00443391 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 141 participants, below the 205-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00443391, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.
Conditions Studied
Interventions
- DRUG ABT-089
Study Locations (20)
Florida
- Site Reference ID/Investigator# 6112 - Jacksonville
- Site Reference ID/Investigator# 6096 - Maitland
- Site Reference ID/Investigator# 6105 - Tampa
Arizona
- Site Reference ID/Investigator# 6109 - Mesa
- Site Reference ID/Investigator# 6765 - Mesa
California
- Site Reference ID/Investigator# 6100 - Lafayette
- Site Reference ID/Investigator# 6107 - San Diego
Texas
- Site Reference ID/Investigator# 6103 - Austin
- Site Reference ID/Investigator# 6104 - Lake Jackson
Georgia
- Site Reference ID/Investigator# 6094 - Smyrna
Kansas
- Site Reference ID/Investigator# 6111 - Newton
Michigan
- Site Reference ID/Investigator# 6113 - Farmington Hills
Nebraska
- Site Reference ID/Investigator# 6110 - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00443391
The ClinicalTrials.gov registry entry for NCT00443391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (31% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which ABT-089 is the first listed.
NCT00443391 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00443391 about?
NCT00443391 is a clinical study titled "A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)". The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.
What is the current status of trial NCT00443391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2007-02. Estimated completion is 2008-10.
What conditions does trial NCT00443391 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00443391?
The interventions under investigation include: ABT-089 (DRUG).
Who is sponsoring clinical trial NCT00443391?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443391 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
COMPLETED · Phase 2
-
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.